Concepedia

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

Thomas Först, Robert Guthrie, Ronald Goldenberg, Jacqueline Yee, Ujjwala Vijapurkar, Gary Meininger, Peter Stein

Diabetes Obesity and Metabolism · 2014 · 249 citations · 25 references

DOIFull text

Open access

Abstract

Canagliflozin improved glycaemic control, reduced body weight and systolic BP, and was generally well tolerated in patients with T2DM on metformin and pioglitazone over 52 weeks.

References

25

Standards of Medical Care in Diabetes—2013

Diabetes Care · 2012 · 4.4K citations · Full text

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

S. E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia · 2012 · 3.9K citations · Full text

, , +10

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

William T. Cefalu, Lawrence A. Leiter, Kun‐Ho Yoon et al. · The Lancet · 2013 · 718 citations

, , +8

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Kaj Stenlöf, William T. Cefalu, Kyung‐Ah Kim et al. · Diabetes Obesity and Metabolism · 2012 · 606 citations · Full text

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Richard M. Bergenstal, Carol Wysham, Leigh MacConell et al. · The Lancet · 2010 · 605 citations

, , +8